Online citations, reference lists, and bibliographies.
← Back to Search

Technology Of Stable, Prolonged-release Eye-drops Containing Cyclosporine A, Distributed Between Lipid Matrix And Surface Of The Solid Lipid Microspheres (SLM).

E. Wolska, M. Sznitowska
Published 2013 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The aim of this study was to prepare solid lipid microspheres (SLM) with incorporated Cyclosporine A (Cs), suitable for ocular application. For this purpose, SLM were formulated by using different lipids and three different nonionic surfactants. The SLM were produced using a hot emulsification method. The SLM dispersions contained 10, 20 or 30% of lipid (w/w) and up to 2% (w/w) of Cs. The size of the microspheres with Cs ranged from 1 to 15 μm. Physically stable SLM with Cs were prepared using Compritol, as a lipid matrix, and Tween 80, as a surfactant. In contrast, dispersion with Precirol alone, formed semi-solid gels during storage, while in formulations with Precirol and Miglyol, crystals of Cs were observed. In vitro release profile of Compritol formulations showed that 40% of Cs is released within 1h, while the release of the following 40% takes more time, depending on lipid content in the formulations. The large part of Cs, added to SLM formulations (from 45 to 80%), was found on the surface of microparticles, but no drug crystallization occurred during a long-term storage.
This paper references
10.1016/S0168-3659(97)00046-1
Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential
K. Westesen (1997)
10.1016/S0378-5173(03)00229-1
Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets.
J. Hamdani (2003)
10.1016/j.ijpharm.2008.10.003
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products.
J. Pardeike (2009)
10.1111/j.1442-9071.2009.02090.x
Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye
M. Guzey (2009)
10.1016/S0939-6411(03)00138-3
Cyclosporine A delivery to the eye: a pharmaceutical challenge.
F. Lallemand (2003)
10.1016/j.ijpharm.2008.07.028
Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity.
E. Gokce (2008)
10.3109/02713680903261405
Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance and In Vivo Drug Release in Rabbit Eyes
E. Gökçe (2009)
10.3109/02652040902846883
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery
E. Başaran (2010)
10.1016/J.CEJ.2006.03.031
Mesoscale simulation of drug molecules distribution in the matrix of solid lipid microparticles (SLM)
C. Long (2006)
10.1208/pt050227
Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration
V. Sanna (2008)
10.1016/j.addr.2008.09.002
Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.
Jim Jiao (2008)
10.1097/00003226-200107000-00013
Effects of Three Penetration Enhancers on Transcorneal Permeation of Cyclosporine
P. van der Bijl (2001)
The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis.
M. Hingorani (1999)
10.2174/156720108783331069
Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization.
Jigisha K Varia (2008)
10.1016/j.colsurfb.2010.12.024
The size of solid lipid nanoparticles: an interpretation from experimental design.
Carla Vitorino (2011)
10.1097/00003226-200203000-00006
Topical Cyclosporin A in the Management of Therapeutic Keratoplasty for Mycotic Keratitis
H. Perry (2002)
10.1016/S0161-6420(93)31558-7
Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye.
J. K. Milani (1993)
10.1167/IOVS.05-1373
Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study.
Y. He (2006)
10.1089/JOP.1995.11.509
Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection.
B. Gebhardt (1995)
10.1097/00003226-199403000-00006
Influence of Topically Applied Cyclosporine A in Olive Oil on Corneal Epithelium Permeability
J. M. Benítez Del Castillo (1994)
10.1016/J.JBIOTEC.2004.06.007
Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles.
R. H. Muller (2004)
10.3109/10717540903334959
Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium
A. Attama (2009)
10.1111/j.2042-7158.2010.01024.x
Lipid nanoparticles for the delivery of poorly water‐soluble drugs
H. Bunjes (2010)
10.2165/00003088-200544030-00003
Ocular Pharmacokinetics and Safety of Ciclosporin, a Novel Topical Treatment for Dry Eye
D. Tang-Liu (2005)
10.1517/17425247.2.1.75
Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications
S. Jaspart (2005)
The choice of lipids and surfactants for injectable extravenous microspheres.
J. Pietkiewicz (2004)
10.1016/j.ijpharm.2010.10.008
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Jie Shen (2010)
10.1016/S0378-5173(02)00268-5
Incorporation of cyclosporin A in solid lipid nanoparticles (SLN).
E. Ugazio (2002)
10.4172/JBB.1000050
Development and Characterization of Solid-Lipid Microparticles of Highly Insoluble Drug Sirolimus
B. Nanjwade (2011)
10.1016/J.IJPHARM.2005.11.038
The expulsion of lipophilic drugs from the cores of solid lipid microspheres in diluted suspensions and in concentrates.
J. Pietkiewicz (2006)
10.1016/J.EJPS.2005.10.004
Structural investigations on lipid nanoparticles containing high amounts of lecithin.
M. Schubert (2006)
10.1097/00003226-199007000-00003
The collagen shield. A new vehicle for delivery of cyclosporin A to the eye.
J. Reidy (1990)
10.1016/S0168-3659(01)00354-6
Lipid microparticles as a parenteral controlled release device for peptides.
H. Reithmeier (2001)



This paper is referenced by
10.1002/9781118675748.ch9
Ophthalmic Dosage Forms
Christian Simroth-Loch (2019)
10.3390/pharmaceutics12070664
Analytical Techniques for the Assessment of Drug-Lipid Interactions and the Active Substance Distribution in Liquid Dispersions of Solid Lipid Microparticles (SLM) Produced de novo and Reconstituted from Spray-Dried Powders
E. Wolska (2020)
TERNARY SOLID DISPERSIONS OF OMEPRAZOLE FOR ENHANCING SOLUBILITY AND DISSOLUTION
K. ArshadAhmedKhan (2015)
10.1016/j.ijpharm.2015.08.059
Design of lipid microparticle dispersions based on the physicochemical properties of the lipid and aqueous phase.
A. Lauterbach (2015)
10.1016/j.jconrel.2016.01.056
Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.
M. Guada (2016)
10.1002/bmc.3132
Development and validation of UHPLC method for the determination of cyclosporine A in biological samples.
O. Szerkus (2014)
10.1016/j.ejps.2018.05.015
Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model
E. Wolska (2018)
10.1016/j.ejpb.2016.10.023
The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN)
M. Sznitowska (2017)
10.1039/C5RA17423F
Quercetin delivery to porcine cornea and sclera by solid lipid nanoparticles and nanoemulsion
C. Liu (2015)
10.1517/17425247.2014.935335
Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals
M. H. Aburahma (2014)
10.1080/17425247.2017.1329297
Doxycycline hydrochloride-metronidazole solid lipid microparticles gels for treatment of periodontitis: development, in-vitro and in-vivo clinical evaluation
H. Gad (2017)
NOVEL APPROACHES IN THE PREPARATION OF SOLID DISPERSION ON SOLUBILITY : A REVIEW
R. Jagadeesan (2013)
10.1016/j.ejpb.2017.03.006
Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts
F. Lallemand (2017)
10.1002/adhm.201700733
Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation
Michelle L. Ratay (2017)
Semantic Scholar Logo Some data provided by SemanticScholar